文献速递脑血管病

血清补体C3升高与缺血性卒中不良临床结局相关

Increased Serum Complement C3 Levels Are Associated With Adverse Clinical Outcomes After Ischemic Stroke.
PubMed 文献 · Stroke · 2021-02-01

该前瞻性研究纳入26家医院3474例缺血性卒中患者,检测基线血清补体C3并随访3个月临床结局。多因素调整后,补体C3升高与主要结局风险增加相关,每增加1个SD(对数转换)风险增加13%,提示其可能作为预后生物标志物。

要点

  • 基线血清补体C3升高与缺血性卒中3个月死亡和主要残疾复合结局风险增加独立相关。
  • 补体C3每增加1个SD(对数转换),主要结局风险增加13%(95%CI 2%-25%)。
  • 将补体C3加入常规风险因素可改善主要结局的风险预测。

核心结论

  • 基线高血清补体C3水平与缺血性卒中后3个月不良临床结局风险增加相关,提示其可能是有价值的预后生物标志物。

研究设计与样本

  • 前瞻性研究,纳入26家参与医院的3474例缺血性卒中患者,检测血清补体C3并收集卒中后3个月临床结局。

主要发现

  • 3个月随访期间866例(25.4%)发生主要结局。
  • 多因素调整后,比较补体C3最高与最低三分位组,主要结局风险增加(OR 1.30,95%CI 1.02-1.65;Ptrend=0.038)。
  • 对数转换补体C3每增加1个SD,主要结局风险增加13%(95%CI 2%-25%)。
  • 多因素调整样条回归模型显示补体C3与主要结局风险呈线性关系(Plinearity=0.022)。
  • 将补体C3加入常规风险因素可改善主要结局风险预测(NRI 8.87%,P=0.028;IDI 0.19%,P=0.029)。

关键数值与推荐

  • 主要结局为卒中后3个月死亡和主要残疾(改良Rankin量表评分≥3)的复合结局。
  • 次要结局包括主要残疾、死亡和血管事件。

临床怎么用

  • 血清补体C3或可作为缺血性卒中预后评估的辅助生物标志物,但需进一步验证后方可用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Complement C3 has been implicated in inflammation and ischemia/reperfusion injury, but its impact on the prognosis of ischemic stroke remains unclear. Aim of this study was to prospectively investigate the association between serum complement C3 and adverse clinical outcomes after ischemic stroke. METHODS: We measured serum complement C3 levels for 3474 patients with ischemic stroke in 26 participating hospitals and collected data of clinical outcomes at 3 months after ischemic stroke. The primary outcome was composite outcome of death and major disability (modified Rankin Scale score ≥3) at 3 months after stroke onset and secondary outcomes included major disability, death, and vascular events. RESULTS: During 3 months of follow-up, 866 participants (25.4%) developed primary outcome. After multivariate adjustment, elevated serum complement C3 levels were associated with increased risk of primary outcome (odds ratio, 1.30 [95% CI, 1.02-1.65]; Ptrend=0.038) when 2 extreme tertiles were compared. Each SD increase of log-transformed complement C3 was associated with 13% (95% CI, 2%-25%) increased risk of primary outcome. Multivariable-adjusted spline regression model showed a linear relationship between serum complement C3 and the risk of primary outcome (Plinearity=0.022). Addition of serum complement C3 to conventional risk factors significantly improved the risk prediction of primary outcome (net reclassification index: 8.87%, P=0.028; integrated discrimination index: 0.19%, P=0.029). CONCLUSIONS: High serum complement C3 levels at baseline were associated with increased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting that serum complement C3 may be a valuable prognostic biomarker for ischemic stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yang P, Zhu Z, Zang Y, et al. Increased Serum Complement C3 Levels Are Associated With Adverse Clinical Outcomes After Ischemic Stroke. Stroke. 2021. PMID: 33517703. doi:10.1161/STROKEAHA.120.031715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。